HC Wainwright reiterates Buy on Nurix Therapeutics at $32
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating for Nurix Therapeutics, maintaining a price target of $32. The endorsement underscores the firm's continued confidence in the biotechnology company's market performance and future prospects.
*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Robert Burns has reaffirmed a Buy rating for Nurix Therapeutics, maintaining a price target of $32. The endorsement underscores the firm's continued confidence in the biotechnology company's market performance and future prospects.
Analyst Rating and Price Target
The rating update comes as part of a routine review of Nurix Therapeutics' stock. The $32 price target reflects the analyst's valuation of the company's current operational strength and projected growth trajectory.
| Metric | Value |
|---|---|
| Rating | Buy |
| Price Target | $32 |
| Analyst | Robert Burns |
| Firm | HC Wainwright & Co. |
Nurix Therapeutics focuses on developing therapies using its proprietary drug discovery platform. The company's stock trades on the NASDAQ under the ticker symbol NRIX.
What upcoming clinical trial milestones could drive the stock toward the $32 price target?
How might Nurix's proprietary platform attract potential partnership or acquisition interest?
What competitive challenges could Nurix face in the biotechnology sector?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
